|
Synonyms: RC18 | Tai'ai®
telitacicept is an approved drug (China (2021))
Compound class:
Peptide or derivative
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
|
| References |
|
1. Dhillon S. (2021)
Telitacicept: First Approval. Drugs, 81 (14): 1671-1675. [PMID:34463932] |
|
2. Ding J, Cai Y, Deng Y, Jiang X, Gao M, Lin Y, Zhao N, Wang Z, Yu H, Lv W et al.. (2021)
Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. Front Neurol, 12: 596791. [PMID:33868140] |
|
3. La Cava A. (2013)
Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol, 148 (3): 322-7. [PMID:23269199] |
|
4. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. (2021)
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol, 43 (6): 666-673. [PMID:34519594] |
|
5. Yao X, Ren Y, Zhao Q, Chen X, Jiang J, Liu D, Hu P. (2021)
Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci, 159: 105704. [PMID:33440243] |
